Real-World Outcomes in the Management of Refractory Psychosis / Amir Krivoy en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No. 5 (Septiembre - Octubre)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No. 5 (Septiembre - Octubre) . - pp. 6-13 Título : Real-World Outcomes in the Management of Refractory Psychosis Tipo de documento: texto impreso Autores: Amir Krivoy, Autor ; Dan Joyce, Autor Fecha de publicación: 2019 Artículo en la página: pp. 6-13 Idioma : Inglés (eng) Palabras clave: Psicosis refractaria, Clozapina. Resumen: Clozapine is the only medication approved for those patients with schizophrenia who do not achieve a clinical response to standard antipsychotic treatment, yet it is still underused. Furthermore, in the case of a partial or minimal response to clozapine treatment, there is no clarity on the next pharmacologic intervention. Link: ./index.php?lvl=notice_display&id=21309 [artículo] Real-World Outcomes in the Management of Refractory Psychosis [texto impreso] / Amir Krivoy, Autor ; Dan Joyce, Autor . - 2019 . - pp. 6-13. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No. 5 (Septiembre - Octubre) . - pp. 6-13 Palabras clave: Psicosis refractaria, Clozapina. Resumen: Clozapine is the only medication approved for those patients with schizophrenia who do not achieve a clinical response to standard antipsychotic treatment, yet it is still underused. Furthermore, in the case of a partial or minimal response to clozapine treatment, there is no clarity on the next pharmacologic intervention. Link: ./index.php?lvl=notice_display&id=21309

---

1 (1 - 1 / 1)